Form 4: Organogenesis Holdings Inc. Executive Lori Freedman Reports Stock and Option Awards

Lori Freedman, Chief Admin. and Legal Officer of Organogenesis Holdings Inc., reports the acquisition of restricted stock units and stock options.

Summary

• Lori Freedman, Chief Admin. and Legal Officer of Organogenesis Holdings Inc., filed a Form 4 on February 21, 2025.
• The report details the grant of 162,047 restricted stock units (RSUs) and an option to purchase 167,625 shares of Class A Common Stock at an exercise price of $3.53 on February 19, 2025.
• The RSUs vest in equal annual installments over four years beginning February 15, 2025.
• The stock options also become exercisable in equal annual installments over four years beginning February 15, 2025.
• Following these transactions, Freedman beneficially owns 594,195 shares of Class A Common Stock and 167,625 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the company's future, but it's a routine transaction.

Positives

• The grant of RSUs and stock options to a key executive like Lori Freedman aligns her interests with those of the shareholders.
• The vesting schedule of four years for both RSUs and stock options encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted equity.

Industry Context

This type of equity grant is a common practice in publicly traded companies to incentivize and retain key executives.

Stakeholder Impact

• The equity grants could have a slightly dilutive effect on existing shareholders.
• The grants incentivize the executive to work towards increasing shareholder value.

Key Dates

Keywords

Organogenesis Holdings Inc., Lori Freedman, Form 4, RSU, Stock Options, Beneficial Ownership, Equity Incentive Plan